See high -growing technology stocks in Europe in March 2025

In the middle of a background of global trade policy uncertainty and the mixed economic signals, the European market has shown resilience, with the Germany's Dax index increasing by over 2%, although the concerns are impaired. Since the European Central Bank adapts its monetary policy to cope with inflation and growth problems, investors observe the high-growing tech shares that can benefit from increased infrastructure expenditure and innovation-driven options.

name	Sales growth	Profit growth	Growth assessment
Elicera therapeutics	63.53%	97.24%	★★★★earch
Pharma Mar	24.24%	40.82%	★★★★earch
Bonesupport Holding	30.48%	50.17%	★★★★earch
CD project	27.71%	41.31%	★★★★earch
Yubico	20.88%	26.53%	★★★★earch
Xbrane Biopharma	73.73%	139.21%	★★★★earch
Devyser Diagnostics	26.50%	94.65%	★★★★earch
Elliptical laboratories	49.76%	88.21%	★★★★earch
Ascelia Pharma	46.09%	66.93%	★★★★earch
Scolon	29.71%	91.18%	★★★★earch

Click here to display the full list of 246 shares from our European high -awake technician and AI shares.

Let us get out of the screen in some first -class options.

Simply wall st -growth level: ★★★★ ☆itch

Overview: Zealand Pharma A/S is a biotechnology company that focuses on the discovery, development and marketing of medication on a peptide basis in Denmark and the USA, with a market capitalization of DKK42.53 billion.

Operations: Zealand Pharma mainly achieves revenue from his biotechnology segment, which corresponds to -62.69 million on DKKKK. The company's business activity is about peptide base medication in Denmark and the United States.

Zealand Pharma, which navigates with high operations through the biotech landscape, shows a robust sales growth course of 22.3% per year and significantly exceeds the 8.9% of the Danish market. Despite the current unprofitable and a forecast average decline in profit of 4.7% in the next three years, strategic maneuvers such as recent cooperation with Roche and an aggressive attitude underneath underline their commitment to innovations. The inclusion of the company in the OMX Nordic 40-Index and the ongoing efforts to expand its product pipeline with strict FDA engagements underline both challenges and potential when using the latest biotechnological progress for growth.

CPSE: zeal yields and sales growth as on March 2025

Simply wall st -growth level: ★★★★★ ☆

Overview: Partec AG specializes in the development, production and delivery of supercomputer and quantum computer solutions with a market capitalization of € 280 million.

Operations: Partec AG mainly achieves income from its computer hardware segment, which corresponds to around € 48.67 million.

In the middle of a redesign of its management team, Partec AG continues to lead significant progress in the Tech industry with annual sales growth forecast of 32.5%and exceeds the average of 5.8%. Despite the current unprofitable, the company is a turn with a profit that will increase by 41.7% annually in the next three years. The recent presentations at important international technology conferences underline the commitment of Partec to remain at the top of the powerful computer solutions, and signal robust future prospects despite a volatile course price and ongoing management transitions.

DB: JY0 sales and output traces as on March 2025

Simply wall st -growth level: ★★★★ ☆itch

Overview: Nordhealth as a company that offers health software solutions in different countries, including Norway, Finland, Sweden, Denmark and Germany with a market capitalization of NOK3.11 billion NOK.

Operations: Nordhealth, as it occurs in the software software for health software, which is mainly offered in several countries. The company focuses on providing digital tools to improve health and efficiency.

Nordhealth, a player on the cloud-based veterinary software market, navigates a transformative phase with remarkable strategic movements. Recently the appointment of Alexander Cram as CFO, the company intends to strengthen its financial leadership in the middle of a challenging, yet improved budget landscape to reduce the fourth quarter to € 12.14 million compared to the previous year from EUR 10.17 million and the loss of € 3.4 million to EUR 2.81 million. Proving Cloud is particularly promising through a pilot program with a large US veterinary group to North America, which improves the customer base and stabilizes the sources of income in this high-growth sector despite the current unfitability and volatility of the share price.

Ob: Nordh profit and sales growth as in March 2025

This article by Simply Wall Street is a general nature. We offer comments based on historical data and analyst forecasts that only use an impartial methodology, and our articles are not intended as financial advice. It is not a recommendation to buy or sell shares, and does not take into account your goals or your financial situation. We would like to use a long -term focused analysis by basic data. Note that our analysis may not take into account the latest record -sensitive announcements or qualitative material. Simply Wall Street has no position in the stocks mentioned.

In this article, companies discussed include CPSE: ZEAL DB: JY0 and OB: Nordh.

Have feedback on this article? Worried about the content? Make sure you contact us. Alternatively, send an email to Redaktionsteam@simplywallst.com

See high -growing technology stocks in Europe in March 2025

Related posts:

13 of the most wanted criminals of the New York state for March 2025

The state of Ohio's football program may have found its replacement for Larry Johnson

Half -life 2 RTX Playable Demo will be published on March 18